ArticleNature2025
IL-33-activated ILC2s induce tertiary lymphoid structures in pancreatic cancer.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers.
0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
86 citing papers in PubMed.
- Deep learning-based CT model for non-invasive prediction of tertiary lymphoid structures in pancreatic cancer: a multicenter study with prospective validation in an immunochemotherapy cohort.Journal for immunotherapy of cancer · 2026Trial
- Asynchronous Evolution of Epithelium and Stroma Differentiates Precursor Lesions from Pancreatic Cancer.Cancer discovery · 2026Article
- Heterogeneity in cancer: molecular mechanisms and therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- Immunogenic cell death and tertiary lymphoid structures: bridging tumour cell death and immune organization.Nature reviews. Immunology · 2026Review
- Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma.Cancer science · 2026Article
- The spatial architecture of tumor immunity: Emerging predictive biomarkers across cancer.Immunologic research · 2026Review
- B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Tertiary lymphoid structures in cancer: their development, composition, clinical prognosis, and the drivers of the anti-tumor responses.Molecular biomedicine · 2026Review
- Interleukin-33 and its receptor: multifaceted roles and emerging therapeutic potential.Nature reviews. Immunology · 2026Review
- Review
- DAMPs, PAMPs, and Alarmins: From Mechanism to Therapy.MedComm · 2026Review
- FTU-Seek: Foundation Model-Guided Hard-Negative Learning for Sparse Functional Tissue Unit Segmentation.Biomedicines · 2026Article
- [CRISPR-Cas9 activation screening identifies candidate chemokine regulators of ter-tiary lymphoid structure formation in bladder cancer].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Article
- Formation of tertiary lymphoid structures drives Parkin antitumor immunity.Science advances · 2026Article
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Oncogenic Kras targeting with MRTX1133 or Daraxonrasib specifically synergize with anti-CTLA4 to promote anti-tumor immunity in pancreatic cancer.Nature communications · 2026Article
- Tertiary lymphoid structures in neuroinflammation coordinate neuroimmune homeostasis and pathological progression.Journal of neuroinflammation · 2026Review
- The future of tertiary lymphoid structures in cancer immunotherapy as biomarkers and therapeutic targets.Nature cancer · 2026Article
- Cancer Heterogeneity and Cancer Cell Plasticity: Molecular Mechanisms and Precision Therapy.MedComm · 2026Review
- Tumor infiltrating B cells and tertiary lymphoid structures in pancreatic cancer prognosis and therapy.iScience · 2026Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Masataka Amisaki *Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4153-4036
Abderezak Zebboudj *Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4708-5211
Hiroshi YanoJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-3098-2629
Siqi Linsey ZhangImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0009-0001-4436-2746
George PayneImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Adrienne Kaya ChandraImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rebecca YuImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pablo GuaspImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3655-916X
Zachary M SethnaImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Akihiro OhmotoImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Luis A RojasImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9218-4086
Charlotte ChengImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Theresa WatersImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alexander SolovyovComputational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Stephen MartisComputational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1735-2347
Ashley S DoaneComputational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Charlotte ReicheImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Emmanuel M BrunoImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2885-1133
Martina MilighettiImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-4170-8796
Kevin SoaresHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-0406-017X
Zagaa OdgerelImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
John Alec MoralHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Julia N ZhaoHepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4352-7748
Mithat GönenDepartment of Biostatistics & Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-8683-8477
Rui GardnerFlow Cytometry Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7270-5136
Alexei V TumanovDepartment of Microbiology, Immunology & Molecular Genetics, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.
Abdul G KhanTri-Institutional Therapeutics Discovery Institute, New York, NY, USA.
Olivia VergnolleTri-Institutional Therapeutics Discovery Institute, New York, NY, USA.ORCID 0000-0001-6885-6145
Elisabeth K NyakaturaTri-Institutional Therapeutics Discovery Institute, New York, NY, USA.
Ivo C LorenzTri-Institutional Therapeutics Discovery Institute, New York, NY, USA.
Manuel BacaTri-Institutional Therapeutics Discovery Institute, New York, NY, USA.
Erin PattersonThe Olayan Center for Cancer Vaccines, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Benjamin GreenbaumComputational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6153-8793
David ArtisJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-1753-4100
Taha MerghoubSandra and Edward Meyer Cancer Center, Weill Cornell Medicine, Weill Cornell Medical College, New York, NY, USA.ORCID 0000-0002-1518-5111
Vinod P BalachandranImmuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. balachav@mskcc.org.ORCID 0000-0002-2956-223X
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTotal Neoadjuvant Therapy (TNT) for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaP50CA257881 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christine A Iacobuzio-Donahue, Eileen Mary O'Reilly · 2022 to 2026
$14.3MRegulation of protective immunity following enteric viral infectionU01AI095608 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ARTIS, DAVID, SONNENBERG, GREGORY F · 2011 to 2025
$11.0MMicrobiota-derived metabolites and the regulation of host immunity and inflammation (Diversity Supplement)R01AI172027 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI David Artis, Chun-Jun Guo · 2022 to 2026
$4.4MNeuroimmune Regulation of Atopic DermatitisR01AR070116 · NIAMS · WASHINGTON UNIVERSITY · PI KIM, BRIAN · 2016 to 2021
$3.8MRegulation and function of innate lymphoid cells in the gutR01AI095466 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ARTIS, DAVID · 2011 to 2022
$3.7MNeuropeptide-mediated regulation of antihelminth immunityR01AI151599 · NIAID · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI ARTIS, DAVID, SIRACUSA, MARK CHRISTOPHER · 2020 to 2024
$3.2MNeuro-immune regulation of intestinal inflammationR01DK126871 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI ARTIS, DAVID · 2020 to 2024
$3.2MGroup 2 Innate Lymphoid Cell Regulation of Pancreatic Cancer ImmunityR01CA262516 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BALACHANDRAN, VINOD P, MERGHOUB, TAHA · 2022 to 2025
$2.8MDietary Regulation of Intestinal Inflammation and RepairR01DK132244 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI ARTIS, DAVID, GUO, CHUN-JUN · 2022 to 2025
$2.7MNeuro-immune regulation of inter-organ skin-gut inflammationK99AI180354 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI YANO, HIROSHI · 2024 to 2025
$257kNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA257881NCI NIH HHS R01 CA262516NIAID NIH HHS K99 AI180354NIAID NIH HHS R01 AI095466NIAID NIH HHS R01 AI151599NIAID NIH HHS R01 AI172027NIAID NIH HHS U01 AI095608NIAMS NIH HHS R01 AR070116NIDDK NIH HHS R01 DK126871NIDDK NIH HHS R01 DK132244
Abstract
Tertiary lymphoid structures (TLSs) are de novo ectopic lymphoid aggregates that regulate immunity in chronically inflamed tissues, including tumours. Although TLSs form due to inflammation-triggered activation of the lymphotoxin (LT)-LTβ receptor (LTβR) pathway
Indexed as
Carcinoma, Pancreatic DuctalImmunity, InnateInterleukin-33LymphocytesPancreatic NeoplasmsTertiary Lymphoid StructuresAlarminsAnimalsColitisFemaleHumansImmunotherapyInflammationMaleMiceMice, Inbred C57BLAlarminsIL33 protein, humanIl33 protein, mouseInterleukin-33Recombinant Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.